Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 2 |
2019 | 2 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Page 1
Mutant p53 in breast cancer: potential as a therapeutic target and biomarker.
Breast Cancer Res Treat. 2018 Jul;170(2):213-219. doi: 10.1007/s10549-018-4753-7. Epub 2018 Mar 21.
Breast Cancer Res Treat. 2018.
PMID: 29564741
Review.
HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells.
McDermott MSJ, Conlon N, Browne BC, Szabo A, Synnott NC, O'Brien NA, Duffy MJ, Crown J, O'Donovan N.
McDermott MSJ, et al.
Cancers (Basel). 2019 Feb 8;11(2):197. doi: 10.3390/cancers11020197.
Cancers (Basel). 2019.
PMID: 30743996
Free PMC article.
Item in Clipboard
Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells.
Gaule P, Mukherjee N, Corkery B, Eustace AJ, Gately K, Roche S, O'Connor R, O'Byrne KJ, Walsh N, Duffy MJ, Crown J, O'Donovan N.
Gaule P, et al.
Cancers (Basel). 2019 Apr 17;11(4):548. doi: 10.3390/cancers11040548.
Cancers (Basel). 2019.
PMID: 30999598
Free PMC article.
Item in Clipboard
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
Eustace AJ, Conlon NT, McDermott MSJ, Browne BC, O'Leary P, Holmes FA, Espina V, Liotta LA, O'Shaughnessy J, Gallagher C, O'Driscoll L, Rani S, Madden SF, O'Brien NA, Ginther C, Slamon D, Walsh N, Gallagher WM, Zagozdzon R, Watson WR, O'Donovan N, Crown J.
Eustace AJ, et al.
BMC Cancer. 2018 Oct 11;18(1):965. doi: 10.1186/s12885-018-4852-1.
BMC Cancer. 2018.
PMID: 30305055
Free PMC article.
Item in Clipboard
Cite
Cite